113 related articles for article (PubMed ID: 9796987)
61. Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer.
Jahedi M; Meshkini A
Colloids Surf B Biointerfaces; 2023 Jun; 226():113333. PubMed ID: 37141773
[TBL] [Abstract][Full Text] [Related]
62. A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations.
Danhauser LL; Rustum YM
J Lab Clin Med; 1979 Jun; 93(6):1047-53. PubMed ID: 438606
[TBL] [Abstract][Full Text] [Related]
63. [Physicochemical compatibility of 5-fluorouracil (new french preparation) and folinic acid].
Milano G; Renée N
Bull Cancer; 1995 Mar; 82(3):189-95. PubMed ID: 7655146
[TBL] [Abstract][Full Text] [Related]
64. Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities.
Etienne MC; Fischel JL; Formento P; Schneider M; Guillot T; Bardon M; Milano G
Biochem Pharmacol; 1993 Nov; 46(10):1767-74. PubMed ID: 8250962
[TBL] [Abstract][Full Text] [Related]
65. Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.
Bernard S; Etienne MC; Fischel JL; Formento P; Milano G
Br J Cancer; 1991 Feb; 63(2):303-7. PubMed ID: 1997110
[TBL] [Abstract][Full Text] [Related]
66. An in vitro examination of a 5-fluorouracil regimen involving continuous venous infusion using cultured cell lines derived from ovarian cancers.
Saga Y; Suzuki M; Sato I; Shirasaka T
Oncol Rep; 2000; 7(3):625-8. PubMed ID: 10767380
[TBL] [Abstract][Full Text] [Related]
67. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data.
Ratti M; Hahne JC; Toppo L; Castelli E; Petrelli F; Passalacqua R; Barni S; Tomasello G; Ghidini M
Ther Adv Med Oncol; 2019; 11():1758835919853954. PubMed ID: 31210799
[TBL] [Abstract][Full Text] [Related]
68. Folinic acid effect on 5-fluorouracil kinetics in vivo.
Herrmann R; Reuter J; Port R; Osswald H
J Cancer Res Clin Oncol; 1988; 114(1):87-90. PubMed ID: 3258310
[TBL] [Abstract][Full Text] [Related]
69. Neuroprotective Effects of an Aqueous Extract of
Yi JM; Shin S; Kim NS; Bang OS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30934631
[TBL] [Abstract][Full Text] [Related]
70. Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment.
Negrei C; Hudita A; Ginghina O; Galateanu B; Voicu SN; Stan M; Costache M; Fenga C; Drakoulis N; Tsatsakis AM
Front Pharmacol; 2016; 7():172. PubMed ID: 27445811
[TBL] [Abstract][Full Text] [Related]
71. Freddie H. Fu, MD 1951-2021.
J Bone Joint Surg Am; 2021 Dec; 103(24):2340. PubMed ID: 37279294
[No Abstract] [Full Text] [Related]
72. Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Frerker B; Bock F; Cappel ML; Kriesen S; Klautke G; Hildebrandt G; Manda K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373535
[TBL] [Abstract][Full Text] [Related]
73. Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?
Azmy A; Abdelwahab S; Yassen M
ISRN Oncol; 2013; 2013():358538. PubMed ID: 23533808
[TBL] [Abstract][Full Text] [Related]
74. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
75. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G;
J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941
[TBL] [Abstract][Full Text] [Related]
76. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
77. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.
Correale P; Cusi MG; Micheli L; Nencini C; Del Vecchio MT; Torino F; Aquino A; Bonmassar E; Francini G; Giorgi G
Invest New Drugs; 2006 Mar; 24(2):99-110. PubMed ID: 16502353
[TBL] [Abstract][Full Text] [Related]
78. Oxaliplatin: in operable colorectal cancer.
Keam SJ; Dunn CJ; Figgitt DP
Drugs; 2005; 65(1):89-96; discussion 97-8. PubMed ID: 15610052
[TBL] [Abstract][Full Text] [Related]
79. Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Guglielmi A; Barni S; Zaniboni A; Pella N; Belvedere O; Beretta GD; Grossi F; Frontini L; Puglisi F; Labianca R; Sobrero A;
Br J Cancer; 2004 Oct; 91(8):1428-33. PubMed ID: 15381935
[TBL] [Abstract][Full Text] [Related]
80. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
